Cardiovascular disease in chronic kidney disease: Untying the Gordian knot

International Journal of Clinical Practice

Volumn 67, Issue 1, 2013, Pages 14-31

  Hajhosseiny, R ^a   Khavandi, K ^b   Goldsmith, D J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALBUMIN; ALPHA TOCOPHEROL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; CREATINE KINASE; CREATININE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; EZETIMIBE PLUS SIMVASTATIN; FIBROBLAST GROWTH FACTOR 23; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYOGLOBIN; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; RAMIPRIL; TROPONIN; TROPONIN T; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ALBUMINURIA; ANGIOCARDIOGRAPHY; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE REGULATION; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; INFLAMMATION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MICROALBUMINURIA; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ADRENERGIC BETA-AGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIFE STYLE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84871445986     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02954.x     Document Type: Review

References (219)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl. 1): S1-266.
2. Archibald G, Bartlett W, Brown A, et al., UK Consensus Conference on Early Chronic Kidney Disease-6 and 7 February 2007. Nephrol Dial Transplant 2007; 22: 2455-7.
3. http://www.usrds.org/adr.htm UADRUSRDSWs (accessed 15 October 2011).
4. Daly C,. Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 2007; 22 (Suppl. 9): 19-25.
5. Foley RN, Murray AM, Li S, et al., Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-95.
6. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH,. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-63.
7. Landray MJ, Emberson JR, Blackwell L, et al., Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010; 56: 1082-94.
8. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I,. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26: 142-8.
9. Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P,. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007; 49: 37-45.
10. Matsushita K, van der Velde M, Astor BC, et al., Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
12. Ljungman S, Wikstrand J, Hartford M, Berglund G,. Urinary albumin excretion-a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996; 9: 770-8.
13. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M,. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27: 2033-9.
14. Schmieder RE, Mann JF, Schumacher H, et al., Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-64.
15. Stehouwer CD, Smulders YM,. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006; 17: 2106-11.
16. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B,. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Lond) 1995; 88: 629-33.
17. Pontremoli R, Sofia A, Tirotta A, et al., Microalbuminuria is associated with a worse cardiovascular risk profile and target organ damage in essential hypertension. Contrib Nephrol 1996; 119: 115-20.
18. Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM,. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 1710-6.
19. Agewall S, Wikstrand J, Ljungman S, Herlitz H, Fagerberg B,. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? Risk Factor Intervention Study Group. Am J Hypertens 1995; 8: 337-42.
20. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM,. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9: 827-33.
21. Kuusisto J, Mykkanen L, Pyorala K, Laakso M,. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 1995; 91: 831-7.
22. Stehouwer CD,. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19: 778-81.
23. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW,. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
24. Volpe M, Cosentino F, Ruilope LM,. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21: 1213-20.
25. Clausen P, Feldt-Rasmussen B, Jensen G, Jensen JS,. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. Clin Sci (Lond) 1999; 97: 37-43.
26. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B,. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103: 1869-74.
27. Pedrinelli R, Giampietro O, Carmassi F, et al., Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-8.
28. Kario K, Matsuo T, Kobayashi H, et al., Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996; 16: 455-61.
29. Kawagishi T, Matsuyoshi M, Emoto M, et al., Impaired endothelium- dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 1999; 19: 2509-16.
30. Khavandi K, Greenstein AS, Sonoyama K, et al., Myogenic tone and small artery remodelling: insight into diabetic nephropathy. Nephrol Dial Transplant 2009; 24: 361-9.
31. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM,. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study. Kidney Int Suppl 2004; 66: S42-4.
32. Schwedhelm E, Boger RH,. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011; 7: 275-85.
33. Kakimoto Y, Akazawa S,. Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970; 245: 5751-8.
34. Vallance P, Leone A, Calver A, Collier J, Moncada S,. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
35. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D,. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 2006; 21: 2446-51.
36. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R,. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009; 24: 1429-35.
37. Stuhlinger MC, Conci E, Haubner BJ, et al., Asymmetric Dimethyl L-Arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc Res 2007; 75: 417-25.
38. Stam F, van Guldener C, Becker A, et al., Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-45.
39. Yilmaz MI, Stenvinkel P, Sonmez A, et al., Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 2011; 26: 3537-43.
40. Moody WE, Edwards NC, Madhani M, et al., Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 2012. [Epub ahead of print].
41. van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD,. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997; 12 (Suppl. 2): 14-8.
42. van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD,. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 1782-6.
43. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN,. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83: 205-9.
44. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG,. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100-6.
45. Yildiz A, Oflaz H, Pusuroglu H, et al., Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am J Kidney Dis 2003; 41: 616-23.
46. Chaturvedi N, Fuller JH, Taskinen MR,. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001; 24: 2071-7.
47. Kahri J, Groop PH, Elliott T, Viberti G, Taskinen MR,. Plasma cholesteryl ester transfer protein and its relationship to plasma lipoproteins and apolipoprotein A-I-containing lipoproteins in IDDM patients with microalbuminuria and clinical nephropathy. Diabetes Care 1994; 17: 412-9.
48. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J,. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991; 84: 129-39.
49. Castellani LW, Lusis AJ,. ApoA-II versus ApoA-I: two for one is not always a good deal. Arterioscler Thromb Vasc Biol 2001; 21: 1870-2.
50. Tsutsumi K,. Lipoprotein lipase and atherosclerosis. Curr Vasc Pharmacol 2003; 1: 11-7.
51. Stein Y, Stein O,. Lipoprotein lipase and atherosclerosis. Atherosclerosis 2003; 170: 1-9.
52. Barter P,. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2029-31.
53. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC,. Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 1989; 298: 487-90.
54. Jager A, van Hinsbergh VW, Kostense PJ, et al., C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 2002; 22: 593-8.
55. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH,. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-65.
56. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD,. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005; 48: 370-8.
57. Vaccaro F, Mule G, Cottone S, et al., Circulating levels of adhesion molecules in chronic kidney disease correlate with the stage of renal disease and with C-reactive protein. Arch Med Res 2007; 38: 534-8.
58. Costa E, Lima M, Alves JM, et al., Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008; 28: 268-75.
59. Beijers HJ, Ferreira I, Bravenboer B, et al., Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study. Diabetes Care 2009; 32: 1698-703.
60. Gerritsen J, Dekker JM, TenVoorde BJ, et al., Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 2001; 24: 1793-8.
61. Maser RE, Mitchell BD, Vinik AI, Freeman R,. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26: 1895-901.
62. Pop-Busui R,. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33: 434-41.
63. Franceschini N, Rose KM, Astor BC, Couper D, Vupputuri S,. Orthostatic hypotension and incident chronic kidney disease: the atherosclerosis risk in communities study. Hypertension 2010; 56: 1054-9.
64. Fagard RH, De Cort P,. Orthostatic hypotension is a more robust predictor of cardiovascular events than nighttime reverse dipping in elderly. Hypertension 2010; 56: 56-61.
65. Khavandi K, Khavandi A, Asghar O, et al., Diabetic cardiomyopathy-a distinct disease? Best Pract Res Clin Endocrinol Metab 2009; 23: 347-60.
66. Thapa L, Karki P, Sharma SK, Bajaj BK,. Cardiovascular autonomic neuropathy in chronic kidney diseases. JNMA J Nepal Med Assoc 2010; 49: 121-8.
67. Celik A, Melek M, Yuksel S, Onrat E, Avsar A,. Cardiac autonomic dysfunction in hemodialysis patients: the value of heart rate turbulence. Hemodial Int 2011; 15: 193-9.
68. Yang YW, Wu CH, Tsai MK, Kuo TB, Yang CC, Lee PH,. Heart rate variability during hemodialysis and following renal transplantation. Transplant Proc 2010; 42: 1637-40.
69. Stewart GA, Gansevoort RT, Mark PB, et al., Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005; 67: 217-26.
70. Levin A, Singer J, Thompson CR, Ross H, Lewis M,. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-54.
71. Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP,. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009; 76: 652-8.
72. Deo R, Lin F, Vittinghoff E, Tseng ZH, Hulley SB, Shlipak MG,. Kidney dysfunction and sudden cardiac death among women with coronary heart disease. Hypertension 2008; 51: 1578-82.
73. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA,. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 2006; 12: 601-7.
74. Soman SS, Sandberg KR, Borzak S, Hudson MP, Yee J, McCullough PA,. The independent association of renal dysfunction and arrhythmias in critically ill patients. Chest 2002; 122: 669-77.
75. Goldsmith DJ, Covic A,. Coronary artery disease in uremia: etiology, diagnosis, and therapy. Kidney Int 2001; 60: 2059-78.
76. Manske CL, Thomas W, Wang Y, Wilson RF,. Screening diabetic transplant candidates for coronary-artery disease-identification of a low-risk subgroup. Kidney Int 1993; 44: 617-21.
77. Liu H, Yan L, Ma GS, et al., Association of chronic kidney disease and coronary artery disease in 1,010 consecutive patients undergoing coronary angiography. J Nephrol 2011; 25: 219-24.
78. Johnston N, Dargie H, Jardine A,. Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease: ischaemic heart disease. Heart 2008; 94: 1080-8.
79. Karthikeyan V, Ananthasubramaniam K,. Coronary risk assessment and management options in chronic kidney disease patients prior to kidney transplantation. Curr Cardiol Rev 2009; 5: 177-86.
80. De Lima JJG, Sabbaga E, Vieira MLC, et al., Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension 2003; 42: 263-8.
81. Mark PB, Johnston N, Groenning BA, et al., Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69: 1839-45.
82. Sharma R, Pellerin D, Gaze DC, et al., Dobutamine stress echocardiography (DSE) and the resting but not exercise electrocardiograph (ECG) predict severe coronary artery disease (CAD) in end stage renal failure. Heart 2005; 91: A68-A.
83. Fleisher LA, Beckman JA, Brown KA, et al., ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 17: 1707-32.
84. Herzog CA, Marwick TH, Pheley AM, White CW, Rao VK, Dick CD,. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis 1999; 33: 1080-90.
85. Mark PB, Patel RK, Jardine AG,. Screening for coronary artery disease before renal transplantation-rational or rationing? Transplantation 2010; 89: 807-8.
86. Kumar N, Baker CSR, Chan K, et al., Cardiac survival after pre-emptive coronary angiography in transplant patients and those awaiting transplantation. Clin J Am Soc Nephrol 2011; 6: 1912-9.
87. Apple FS, Murakami MM, Pearce LA, Herzog CA,. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50: 2279-85.
88. Clerico A, Caprioli R, Del Ry S, Giannessi D,. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001; 24: 24-30.
89. Cataliotti A, Malatino LS, Jougasaki M, et al., Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76: 1111-9.
90. Ishizaka Y, Yamamoto Y, Tanaka M, et al., Molecular-forms of human brain natriuretic peptide (Bnp) in plasma of patients on hemodialysis (Hd). Clin Nephrol 1995; 43: 237-42.
91. Sabatine MS, Morrow DA, de Lemos JA, et al., Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-3.
92. Bode E, Wuppinger T, Bode T, et al., Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors. Coron Artery Dis 2011; 23: 91-7.
93. Kanderian AS, Francis GS,. Cardiac troponins and chronic kidney disease. Kidney Int 2006; 69: 1112-4.
94. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS,. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002; 40: 2065-71.
95. Li D, Keffer J, Corry K, Vazquez M, Jialal I,. Nonspecific elevation of troponin T levels in patients with chronic renal failure. Clin Biochem 1995; 28: 474-7.
96. Francis GS, Tang WH,. Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Prog Cardiovasc Dis 2004; 47: 196-206.
97. Van Lente F, McErlean ES, DeLuca SA, Peacock WF, Rao JS, Nissen SE,. Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. J Am Coll Cardiol 1999; 33: 471-8.
98. Fernandez-Reyes MJ, Mon C, Heras M, et al., Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. J Nephrol 2004; 17: 721-7.
99. deFilippi C, Wasserman S, Rosanio S, et al., Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353-9.
100. Hruska K, Mathew S, Lund R, Fang Y, Sugatani T,. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int Suppl 2011; 79: S9-13.
101. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM,. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-18.
102. Kestenbaum B, Sampson JN, Rudser KD, et al., Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-8.
103. Dhingra R, Sullivan LM, Fox CS, et al., Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-85.
104. Tonelli M, Sacks F, Pfeffer M, Gao ZW, Curhan G, Invest CT,. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-33.
105. Hruska KA,. Vascular smooth muscle cells in the pathogenesis of vascular calcification. Circ Res 2009; 104: 710-1.
106. Giachelli CM,. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14 (9 Suppl. 4): S300-4.
107. Li X, Yang HY, Giachelli CM,. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-12.
108. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA,. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008; 19: 1092-105.
109. Nakashima K, Zhou X, Kunkel G, et al., The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 17-29.
110. Seiler S, Heine GH, Fliser D,. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009; 76: S34-42.
111. Baum M, Schiavi S, Dwarakanath V, Quigley R,. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005; 68: 1148-53.
112. Marsell R, Grundberg E, Krajisnik T, et al., Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol 2008; 158: 125-9.
113. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB,. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-9.
114. Gutierrez O, Isakova T, Rhee E, et al., Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-15.
115. Fliser D, Kollerits B, Neyer U, et al., Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 2007; 18: 2600-8.
116. Razzaque MS,. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant 2009; 24: 4-7.
117. Faul C, Amaral AP, Oskouei B, et al., FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-408.
118. Gutierrez OM, Januzzi JL, Isakova T, et al., Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-52.
119. Pilz S, Tomaschitz A, Drechsler C, et al., Vitamin D deficiency and heart disease. Kidney Inter Suppl 2011; 1: 111-5.
120. Doorenbos CR, van den Born J, Navis G, de Borst MH,. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 2009; 5: 691-700.
121. Helvig CF, Cuerrier D, Hosfield CM, et al., Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010; 78: 463-72.
122. Bouillon R, Carmeliet G, Verlinden L, et al., Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-76.
123. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU,. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008; 149: 558-64.
124. Li YC, Kong J, Wei MJ, Chen ZF, Liu SQ, Cao LP,. 1,25-Dihydroxyvitamin D-3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38.
125. Simpson RU, Hershey SH, Nibbelink KA,. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-4.
126. Yuan W, Pan W, Kong J, et al., 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-30.
127. O'Connell TD, Simpson RU,. 1,25-Dihydroxyvitamin D3 regulation of myocardial growth and c-myc levels in the rat heart. Biochem Biophys Res Commun 1995; 213: 59-65.
128. O'Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU,. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272: H1751-8.
129. Pilz S, Tomaschitz A, Drechsler C, Dekker JM, Marz W,. Vitamin D deficiency and myocardial diseases. Mol Nutr Food Res 2010; 54: 1103-13.
130. Green JJ, Robinson DA, Wilson GE, Simpson RU, Westfall MV,. Calcitriol modulation of cardiac contractile performance via protein kinase C. J Mol Cell Cardiol 2006; 41: 350-9.
131. Selles J, Bellido T, Boland R,. Modulation of calcium uptake in cultured cardiac muscle cells by 1,25-dihydroxyvitamin D3. J Mol Cell Cardiol 1994; 26: 1593-9.
132. Santillan GE, Vazquez G, Boland RL,. Activation of a beta-adrenergic- sensitive signal transduction pathway by the secosteroid hormone 1,25-(OH)2-vitamin D3 in chick heart. J Mol Cell Cardiol 1999; 31: 1095-104.
133. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF,. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD008175.
134. Thadhani R, Appelbaum E, Pritchett Y, et al., Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-84.
135. http://www.renal.org/clinical/GuidelinesSection/ CardiovascularDiseaseInCKD.aspx CDiC. (accessed 20 October 2011).
136. [No author listed],. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl. 5): v1-52.
137. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care, 2008.
138. van der Zee S, Baber U, Elmariah S, Winston J, Fuster V,. Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol 2009; 6: 580-9.
139. Halimi JM, Giraudeau B, Vol S, et al., Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285-92.
140. Bash LD, Astor BC, Coresh J,. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010; 55: 31-41.
141. Yavuz A, Tuncer M, Gurkan A, et al., Cigarette smoking in renal transplant recipients. Transplant Proc 2004; 36: 108-10.
142. Kasiske BL, Klinger D,. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11: 753-9.
143. Padilla J, Krasnoff J, DaSilva M, et al., Physical functioning in patients with chronic kidney disease. J Nephrol 2008; 21: 550-9.
144. Clyne N,. The importance of exercise training in predialysis patients with chronic kidney disease. Clin Nephrol 2004; 61 (Suppl. 1): S10-3.
145. van Vilsteren MC, de Greef MH, Huisman RM,. The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. Nephrol Dial Transplant 2005; 20: 141-6.
146. Ganji V, Kafai MR,. Demographic, health, lifestyle, and blood vitamin determinants of serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2003; 77: 826-33.
147. Heinz J, Domrose U, Luley C, et al., Influence of a supplementation with vitamins on cardiovascular morbidity and mortality in patients with end-stage renal disease: design and baseline data of a randomized clinical trial. Clin Nephrol 2009; 71: 363-5.
148. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM,. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134-7.
149. Clarke R, Frost C, Sherliker P, et al., Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82: 806-12.
150. Marcus J, Sarnak MJ, Menon V,. Homocysteine lowering and cardiovascular disease risk: lost in translation. Can J Cardiol 2007; 23: 707-10.
151. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP,. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease (vol 15, pg 420, 2004). J Am Soc Nephrol 2004; 15: 420-6.
152. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49 (2 Suppl. 2): S12-154.
153. Sep; NICGGMoTD.
154. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
155. de Boer IH, Sun W, Cleary PA, et al., Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-76.
156. Patel A, MacMahon S, Chalmers J, et al., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
157. Gerstein HC, Miller ME, Byington RP, et al., Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
158. Shurraw S, Tonelli M,. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26: 523-39.
159. Hull RP, Goldsmith DJ,. Nephrotic syndrome in adults. BMJ 2008; 336: 1185-9.
160. Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF,. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2009; CD004289.
161. Sukhija R, Bursac Z, Kakar P, et al., Effect of statins on the development of renal dysfunction. Am J Cardiol 2008; 101: 975-9.
162. Wanner C, Krane V, Marz W, et al., Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
163. Fellstrom BC, Jardine AG, Schmieder RE, et al., Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-407.
164. Seliger SL, Weiss NS, Gillen DL, et al., HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304.
165. Mason NA, Bailie GR, Satayathum S, et al., HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45: 119-26.
166. Green D, Roberts PR, New DI, Kalra PA,. Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis 2011; 57: 921-9.
167. Baigent C, Landray MJ, Reith C, et al., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
168. Grundy SM, Cleeman JI, Merz CN, et al., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
169. Davenport A, Cox C, Thuraisingham R, Grp PTRA,. Achieving blood pressure
170. Shoji T, Tsubakihara Y, Fujii M, Imai E,. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212-20.
171. Burton JO, Jefferies HJ, Selby NM, McIntyre CW,. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009; 4: 1925-31.
172. McIntyre CW, Burton JO, Selby NM, et al., Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008; 3: 19-26.
173. Goldsmith D, Covic A,. Blood pressure control in CKD stage 5D patients-are we more or less certain what to do in 2009? Nephrol Dial Transplant 2009; 24: 3597-601.
174. Levin NW, Kotanko P, Eckardt KU, et al., Blood pressure in chronic kidney disease stage 5D-report from a kidney disease: improving global outcomes controversies conference. Kidney Int 2010; 77: 273-84.
175. Coombes JS, Fassett RG,. Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int 2011; 81: 233-46.
176. Stocker R, Keaney JF Jr,. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478.
177. Galle J,. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001; 16: 2135-7.
178. Ha TK, Sattar N, Talwar D, et al., Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. QJM 1996; 89: 765-9.
179. Cheung AK,. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990; 1: 150-61.
180. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B,. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993; 121: 257-62.
181. Cice G, Ferrara L, D'Andrea A, et al., Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-44.
182. Pun PH, Lehrich RW, Smith SR, Middleton JP,. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007; 2: 491-500.
183. Wali RK, Iyengar M, Beck GJ, et al., Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail 2011; 4: 18-26.
184. Badve SV, Roberts MA, Hawley CM, et al., Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 1152-61.
185. van der Sman-de Beer F, Verhagen C, Rombach SM, et al., ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis. Kidney Int 2005; 68: 2237-43.
186. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G,. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
187. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, Investigators H,. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.
188. Shamseddin MK, Parfrey PS,. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 2011; 7: 145-54.
189. Zannad F, Kessler M, Lehert P, et al., Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-24.
190. Foley RN, Herzog CA, Collins AJ,. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-90.
191. Ishani A, Herzog CA, Collins AJ, Foley RN,. Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int 2004; 65: 1017-25.
192. Griffith TF, Chua BSY, Allen AS, Klassen PS, Reddan DN, Szczech LA,. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003; 42: 1260-9.
193. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O,. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
194. Gaede P, Lund-Andersen H, Parving HH, Pedersen O,. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.
195. Agewall S, Wikstrand J, Ljungman S, Fagerberg B,. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol 1997; 80: 164-9.
196. Jager A, Kostense PJ, Ruhe HG, et al., Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 617-24.
197. Beilin J, Stanton KG, McCann VJ, Knuiman MW, Divitini ML,. Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. Aust N Z J Med 1996; 26: 519-25.
198. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS,. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-7.
199. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K,. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
200. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al., Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-5.
201. Madison JR, Spies C, Schatz IJ, et al., Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program. Arch Intern Med 2006; 166: 884-9.
202. Tillin T, Forouhi N, McKeigue P, Chaturvedi N,. Microalbuminuria and coronary heart disease risk in an ethnically diverse UK population: a prospective cohort study. J Am Soc Nephrol 2005; 16: 3702-10.
203. Yuyun MF, Khaw KT, Luben R, et al., A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004; 159: 284-93.
204. Corona AJ, Martinez DR, Avila MH, et al., Microalbuminuria as a predictor of myocardial infarction in a Mexican population: the Mexico City Diabetes Study. Kidney Int Suppl 2005; 68: S34-9.
205. Ruilope LM, Salvetti A, Jamerson K, et al., Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-25.
206. Schillaci G, Reboldi G, Verdecchia P,. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 886-91.
207. Pahor M, Shorr RI, Somes GW, et al., Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998; 158: 1340-5.
208. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S,. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.
209. Jungers P, Massy ZA, Nguyen Khoa T, et al., Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997; 12: 2597-602.
210. Sechi LA, Zingaro L, De Carli S, et al., Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998; 129: 457-61.
211. Sechi LA, Zingaro L, Catena C, Perin A, De Marchi S, Bartoli E,. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int 1999; 56: 1049-57.
212. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB,. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555-62.
213. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D,. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-9.
214. Hemmelgarn BR, Ghali WA, Quan H, et al., Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 2001; 37: 64-72.
215. Beattie JN, Soman SS, Sandberg KR, et al., Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001; 37: 1191-200.
216. Muntner P, He J, Astor BC, Folsom AR, Coresh J,. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-38.
217. Muntner P, He J, Hamm L, Loria C, Whelton PK,. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-53.
218. Manjunath G, Tighiouart H, Ibrahim H, et al., Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.
219. Manjunath G, Tighiouart H, Coresh J, et al., Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121-9.